HWKN

HAWKINS INC. - 10-Q Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2008, and the six months ended on that date. Hawkins, Inc. operates in three reportable segments: Industrial, Water Treatment, and Pharmaceutical. The company manufactures and distributes bulk chemicals, water treatment products, and pharmaceutical ingredients. As of November 7, 2008, there were 10,253,458 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 67.0% ($32.2M) for the quarter and 50.4% ($48.7M) for the six months compared to the prior year. This was driven primarily by the Industrial and Water Treatment segments due to significant price increases passed through to customers to offset rising raw material costs, alongside an 8% volume increase.
• Margin Compression: Gross margin percentage declined to 22.1% (quarter) and 22.0% (six months) from 24.7% and 24.5% in the prior year. This was primarily due to a LIFO charge resulting from rising raw material inventory costs and a reclassification of certain operating expenses to cost of sales. Excluding these factors, adjusted gross margins would have been 27.7% and 26.7%.
• Segment Performance:
  • Industrial: Sales increased $25.3M (quarter) and $37.2M (six months). Operating income surged due to high demand and supply constraints in the industry.
  • Water Treatment: Sales increased $7.3M (quarter) and $11.7M (six months).
  • Pharmaceutical: Sales decreased 15.0% (quarter) and 3.8% (six months) due to FDA enforcement actions against compounding chemicals, though the company received clearance to sell most affected products in Q3.
• Operating Expenses: SG&A expenses decreased in absolute dollars compared to the prior year, largely due to the reclassification of expenses to cost of sales and the absence of non-recurring acquisition costs present in the prior year.

Guidance, Outlook, and Risks

• Capital Expenditures: The company plans to spend approximately $8.0 million on capacity expansion for the current fiscal year, with $3.5 million incurred through September 30, 2008. A new 77,000 sq. ft. facility in Centralia, Illinois, was acquired for $2.0 million to expand lactate manufacturing.
• Liquidity: The company maintains a strong financial position with $21.9 million in cash and cash equivalents. Management anticipates funding working capital and capital investment needs with internally generated funds and does not expect to engage in significant financing activities.
• Market Risks:
  • Commodity Prices: The company is subject to cyclical fluctuations in commodity chemical prices. While they attempt to pass costs to customers, there is no assurance this will continue.
  • Interest Rate Risk: The company holds a fixed income portfolio of $1.7 million. While subject to interest rate risk, the company intends to hold these investments to maturity or recovery.
• Regulatory Risks: Ongoing FDA enforcement actions in the pharmaceutical sector continue to impact sales volumes, though the company has resolved the majority of restrictions.

Investor Verification Checklist

• LIFO Impact: Verify the magnitude of the LIFO charge ($9.7M inventory reserve) and its specific impact on reported gross margins versus underlying operational performance.
• Pharmaceutical Segment Recovery: Monitor the trajectory of the Pharmaceutical segment sales following FDA clearance to ensure the 15% decline is not a permanent structural shift.
• Working Capital Trends: Review the significant increase in trade receivables ($8.7M increase in cash flow usage) and inventory ($14.9M increase) to ensure collection periods and inventory turnover remain healthy despite sales growth.
• Capital Allocation: Track the execution of the $8.0M capital expenditure plan and the ROI on the new Centralia, Illinois facility.
• Debt Position: Confirm the company remains debt-free (no long-term debt listed on balance sheet) and maintains its current liquidity ratios.